Seeking adults aged 18 years or older with a clinical diagnosis of prurigo nodularis (PN), with ≤ 20% of the total body surface area (BSA) requiring treatment (roughly the size of 20 palm prints or more). Criteria includes having a diagnosis of PN ≥ 3 months before screening, and ≥ 6 pruriginous lesions on ≥ 2 different body areas (such as right and left leg) at screening and baseline.
Participants will receive treatment via an investigational topical agent. Study treatment and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
Peterborough - SKiN Centre for Dermatology
Toronto - North York Research Inc.
Markham - Lynderm Research Inc.
Etobicoke - Kingsway Clinical Research
Similar Trials
No Similar Trials FoundThe following information is from ClinicalTrials.gov
Last Update Posted: September 24, 2023
NCT05764161
Incyte Corporation
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Condition or Disease:
Prurigo Nodularis
Intervention/Treatment:
Drug: Ruxolitinib CreamPhase:
Phase 3
Ages Eligible for Study:
18 Years and 99 Years (Adult)
Sexes Eligible for Study:
All
Inclusion Criteria:
Clinical diagnosis of PN ≥ 3 months before screening.
≥ 6 pruriginous lesions on ≥ 2 different body areas (such as right and left leg) at screening and baseline having a treatment area <20% BSA.
IGA-CPG-S score of ≥ 2 at screening and baseline.
Baseline PN-related WI-NRS score ≥ 7.
Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
Chronic pruritus due to a condition other than PN
Total estimated BSA treatment area (excluding the scalp) > 20%.
Neuropathic and psychogenic pruritus
Active atopic dermatitis lesions within 3 months of screening and baseline.
Uncontrolled thyroid function
Concurrent skin or other serious or unstable medical conditions which may interfere with the evaluation of PN such as immunocompromised status, acute/chronic infections, active malignancy, history of TB, history of DVT/VTE, etc Protocol defined abnormal laboratory results.
Use of any protocol-defined prohibited medication unless a washout is completed or use of medication known to cause itching.
Psoralen and ultraviolet A or ultraviolet B therapy within 4 weeks before baseline or Ultraviolet light therapy or prolonged exposure to natural or artificial sources of ultraviolet radiation (within 2 weeks before baseline
Pregnant or lactating, or considering pregnancy.
History of alcoholism or drug addiction within 1 year
Known allergy or reaction to any of the components of the study drug.
Committed to a mental health institution by virtue of an order issued either by the judicial or the administrative authorities.
Employees of the sponsor or investigator or otherwise dependents of them.
The following participants are excluded in France:
Vulnerable populations according to article L.1121-6 of the French Public Health Code.
Adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code.
Individuals not affiliated with the social security system.
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
register now